A pH-responsive nanoparticle targets the neurokinin 1 receptor in endosomes to prevent chronic pain.

A pH-responsive nanoparticle targets the neurokinin 1 receptor in endosomes to prevent chronic pain.
复制标题

DOI:
10.1038/s41565-019-0568-x
复制
发表时间:
2019-12
影响因子:
38.3
通讯作者:
Bunnett NW
Bunnett NW
中科院分区:
材料科学1区
文献类型:
--
作者:
Ramírez-García PD;Retamal JS;Shenoy P;Imlach W;Sykes M;Truong N;Constandil L;Pelissier T;Nowell CJ;Khor SY;Layani LM;Lumb C;Poole DP;Lieu T;Stewart GD;Mai QN;Jensen DD;Latorre R;Scheff NN;Schmidt BL;Quinn JF;Whittaker MR;Veldhuis NA;Davis TP;Bunnett NW

文献摘要

参考文献

被引文献

相似文献

由于许多纳米药物在细胞内的内体转运机制,纳米颗粒介导的药物递送对于内体内的靶点特别有用。在这里,我们报告了一种pH响应性的软聚合物纳米颗粒的设计,用于靶向酸化的内体,以精确抑制导致慢性疼痛的内体信号传导事件。在慢性疼痛中,P物质(SP)神经激肽1受体(NK1R)从质膜重新分布到酸化的内体,在那里它发出信号以维持疼痛。因此,核内体中的NK1R为疼痛缓解提供了重要靶点。pH响应性纳米颗粒通过网格蛋白和动力蛋白依赖性内吞作用进入细胞,并在含有NK1R的内体中积累。将含有FDA批准的NK 1 R拮抗剂阿瑞匹坦的纳米颗粒鞘内注射到啮齿动物体内后,可以抑制SP诱导的脊髓神经元激活,从而防止疼痛传递。用纳米颗粒治疗可完全和持久地缓解伤害性、炎症性和神经性伤害感受,并为慢性疼痛提供急需的非阿片类药物治疗选择。
Nanoparticle-mediated drug delivery is especially useful for targets within endosomes because of the endosomal transport mechanisms of many nanomedicines within cells. Here, we report the design of a pH-responsive, soft polymeric nanoparticle for the targeting of acidified endosomes to precisely inhibit endosomal signalling events leading to chronic pain. In chronic pain, the substance P (SP) neurokinin 1 receptor (NK1R) redistributes from the plasma membrane to acidified endosomes, where it signals to maintain pain. Therefore, the NK1R in endosomes provides an important target for pain relief. The pH-responsive nanoparticles enter cells by clathrin- and dynamin-dependent endocytosis and accumulate in NK1R-containing endosomes. Following intrathecal injection into rodents, the nanoparticles, containing the FDA-approved NK1R antagonist aprepitant, inhibit SP-induced activation of spinal neurons and thus prevent pain transmission. Treatment with the nanoparticles leads to complete and persistent relief from nociceptive, inflammatory and neuropathic nociception and offers a much-needed nonopioid treatment option for chronic pain.
DOI: 10.3389/fphar.2018.01143
发表时间: 2018
影响因子: 5.6
作者:
Retamal J;Reyes A;Ramirez P;Bravo D;Hernandez A;Pelissier T;Villanueva L;Constandil L
通讯作者: Constandil L
DOI: 10.1073/pnas.0906541106
发表时间: 2009-10-20
影响因子: 11.1
作者:
Murphy, Jane E.;Padilla, Benjamin E.;Bunnett, Nigel W.
通讯作者: Bunnett, Nigel W.
DOI: 10.1124/mol.115.099499
发表时间: 2015-09-01
影响因子: 3.6
作者:
Imlach, Wendy L.;Bhola, Rebecca F.;Christie, Macdonald J.
通讯作者: Christie, Macdonald J.
DOI: 10.1016/j.pain.2014.07.024
发表时间: 2014-10-01
期刊: PAIN
影响因子: 7.4
作者:
Bravo, David;Ibarra, Paula;Constandil, Luis
通讯作者: Constandil, Luis
DOI: 10.1038/nrd.2017.178
发表时间: 2017-12
期刊: Nature reviews. Drug discovery
影响因子: --
作者:
Hauser AS;Attwood MM;Rask-Andersen M;Schiöth HB;Gloriam DE
通讯作者: Gloriam DE